CHIRON |
Science
For Life
TRAFFIC: Conclusions
rFGF-2 is associated with a clinically-relevant increase in PWT in single dose group compared with placebo.
Repeat infusion at 30 days is not better.
IA infusion of rFGF-2 appears safe.
TRAFFIC is a phase II trial and is the first large, randomized, placebo-controlled, therapeutic angiogenesis study to show benefit in its primary efficacy measure.